One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
CapsoVision, Inc.
CV · NCM · Healthcare · Medical Devices
Current price
$6.53
52-week range
$4.50 - $15.37
Market cap
$347.46M
Balance sheet
Healthy
-94.86x Concerning
Net cash $8.39M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 2.5% last year.
- Risk Return on equity was -335.1% last year — the company lost money on shareholders' equity.
What this company does
CapsoVision, Inc.
CapsoVision makes special cameras that look inside your stomach and intestines, like a tiny pill camera you swallow. Most of their money comes from selling these camera systems and the software that helps doctors see the pictures. This matters because it helps doctors find problems in the gut, which can lead to better patient care.
How the company got here
CapsoVision, Inc. started in 2005 with a focus on creating new ways to see inside the human body. The company, originally named Capso Vision Inc., officially became CapsoVision, Inc. in May 2016. Its main goal has always been to develop advanced video imaging devices, particularly for looking at the digestive system. This dedication to internal imaging technology has shaped its journey and product development over the years.
What it actually does
CapsoVision makes and sells special cameras that are small enough to swallow, like a pill. These "capsule endoscopy" systems are designed to take pictures and videos as they travel through the body's digestive tract. This allows doctors to get a clear look inside the stomach, small intestine, and colon without needing more invasive procedures. The company aims to provide doctors with better tools for diagnosing and understanding conditions within the gastrointestinal system.
CapsoCam Plus
This is one of CapsoVision's main products, a capsule endoscopy system specifically designed for visualizing the lining of the small intestine. It's used for both adults and children as young as two years old. The system helps doctors see areas of the small bowel that are hard to reach with traditional endoscopes. Doctors and medical practices pay for these systems to help them diagnose issues like bleeding or inflammation in the small intestine.
CapsoCam Colon and CapsoColon 3D
These products are focused on examining the colon, or large intestine. CapsoCam Colon is used to visualize the colon's lining and to help detect and measure polyps, which are small growths that can sometimes become cancerous. The company is also developing CapsoColon 3D, which is intended for a more detailed view of the large intestine. Hospitals and clinics would use these devices to screen for colon cancer and other colon-related diseases.
CapsoCloud and Reading Services
Beyond the ingestible cameras, CapsoVision offers a suite of supporting services. CapsoCloud is a cloud-based software service that allows doctors to securely access and download the video data from the capsules. They also provide devices like CapsoView for viewing the capsule videos and a retrieval kit (CapsoRetrieve) to help recover the capsule. These services are crucial for making the capsule endoscopy process practical and efficient for healthcare providers.
What management is betting on now
CapsoVision's strategy centers on advancing its internal imaging technology for the gastrointestinal system. The company is focused on improving its existing capsule endoscopy products, like CapsoCam Plus and its colon-focused offerings. A key priority is the development of CapsoColon 3D, aiming for a more comprehensive view of the large intestine. By enhancing these diagnostic tools and their associated cloud services, CapsoVision seeks to become a leading provider of minimally invasive gastrointestinal visualization solutions for doctors and hospitals.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-7.06M
FY2024 Q4
$-5.40M
FY2025 Q1
$-5.03M
FY2025 Q2
$-4.56M
FY2025 Q3
$-5.68M
FY2025 Q4
$-7.69M
FY2026 Q1
$-6.11M
FY2026 Q2
$-8.40M
Revenue
$3.64M
Net income
$-7.48M
Diluted EPS
-0.15
Operating cash flow
$-8.40M
Free cash flow
$-8.40M
Fetching…
Sources
Revenue
$2.79M
Net income
$-7.03M
Diluted EPS
-0.15
Operating cash flow
$-6.07M
Free cash flow
$-6.11M
Fetching…
Sources
Revenue
$3.92M
Net income
$-7.39M
Diluted EPS
3.65
Operating cash flow
$-7.69M
Free cash flow
$-7.69M
Fetching…
Sources
Revenue
$3.54M
Net income
$-7.92M
Diluted EPS
-0.17
Operating cash flow
$-5.67M
Free cash flow
$-5.68M
Fetching…
Sources
Revenue
$3.31M
Net income
$-4.62M
Diluted EPS
-2.02
Operating cash flow
$-4.53M
Free cash flow
$-4.56M
Fetching…
Sources
Revenue
$2.78M
Net income
$-5.38M
Diluted EPS
-2.49
Operating cash flow
$-4.99M
Free cash flow
$-5.03M
Fetching…
Sources
Revenue
$11.76M
Net income
$-4.64M
Diluted EPS
-9.85
Operating cash flow
$-5.40M
Free cash flow
$-5.40M
Fetching…
Sources
Revenue
$2.97M
Net income
$-5.79M
Diluted EPS
-2.79
Operating cash flow
$-7.06M
Free cash flow
$-7.06M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $6.53
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $8.4M - more cash than debt. Interest coverage -94.9x.
Net debt
$-8.39M
Interest coverage
-94.86x
CapsoVision, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here.
Healthy
Worse cushion
Baseline
Better cushion
CV
BASELINE
CapsoVision, Inc.
Total debt $687.00K Interest coverage -94.86x This is the baseline the peer rows are being compared against.
Total debt $0.00 Interest coverage 8.05x This peer still has a real interest-payment cushion, while CV does not.
Total debt $825.92M Interest coverage 41.75x This peer still has a real interest-payment cushion, while CV does not.
Total debt $120.84M Interest coverage 36.48x This peer still has a real interest-payment cushion, while CV does not.
What you should know
The case for and against CV
1 Reward
1 Risk
Rewards
-
Revenue grew 2.5% last year.
Risks
-
Return on equity was -335.1% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
—
P/B
24.83x
P/S
25.01x
EV/EBITDA
-10.63x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
50.9%
Operating margin
-208.1%
Net margin
-214.7%
ROE
-335.1%
ROA
-132.5%
Health
Liquidity and balance-sheet strength
Debt / equity
0.05x
Current ratio
3.35x
Quick ratio
2.20x
Total debt
$687.00K
Total cash
$9.08M
Growth
How the business has been compounding
Revenue TTM
$13.89M
Revenue 5Y CAGR
—
EPS TTM
-0.45
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-27.82M
Free CF TTM
$-22.95M
FCF margin
-165.2%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—